Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose amoxicillin triple therapy versus bismuth-based therapy as second-line eradication for Helicobacter pylori in children
IRCT20191022045195N1Phase 3Completed
- Sponsor
- Qazvin University of Medical Sciences
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of amoxicillin and bismuth subsalicylate in Helicobacter-associated gastritis and Helicobacter pylori infection (2 arms), sponsored by Qazvin University of Medical Sciences. Primary endpoint: Helicobacter pylori eradication rate. Started Nov 2019; status: completed.
02
Drugs
amoxicillinbismuth subsalicylate
03
Conditions
Helicobacter-associated gastritisHelicobacter pylori infection
Beyond the preview
Go deeper on IRCT20191022045195N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191022045195N1.